These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1329 related items for PubMed ID: 22206763

  • 1. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 2. [Current treatment of multiple sclerosis].
    Csépány T.
    Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
    Campbell JD, McQueen RB, Miravalle A, Corboy JR, Vollmer TL, Nair K.
    Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
    [Abstract] [Full Text] [Related]

  • 4. An update on new and emerging therapies for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B.
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635
    [Abstract] [Full Text] [Related]

  • 5. New management algorithms in multiple sclerosis.
    Sorensen PS.
    Curr Opin Neurol; 2014 Jun; 27(3):246-59. PubMed ID: 24759080
    [Abstract] [Full Text] [Related]

  • 6. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 7. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J.
    Mt Sinai J Med; 2011 Aug; 78(2):161-75. PubMed ID: 21425262
    [Abstract] [Full Text] [Related]

  • 8. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013 Aug; 129(5):548-9. PubMed ID: 23520898
    [Abstract] [Full Text] [Related]

  • 9. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ, O'Connor PW.
    Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
    [Abstract] [Full Text] [Related]

  • 10. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [Abstract] [Full Text] [Related]

  • 11. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D, Salanti G.
    Cochrane Database Syst Rev; 2013 Jun 06; (6):CD008933. PubMed ID: 23744561
    [Abstract] [Full Text] [Related]

  • 12. Current management of relapsing-remitting multiple sclerosis.
    Sedal L, Wilson IB, McDonald EA.
    Intern Med J; 2014 Oct 06; 44(10):950-7. PubMed ID: 25302718
    [Abstract] [Full Text] [Related]

  • 13. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C, Tintoré M, Aguilera C.
    Med Clin (Barc); 2012 Sep 22; 139(7):316-8. PubMed ID: 22743277
    [No Abstract] [Full Text] [Related]

  • 14. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

  • 15. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH, Wakefield RA.
    Am J Health Syst Pharm; 2015 Jan 01; 72(1):25-38. PubMed ID: 25511835
    [Abstract] [Full Text] [Related]

  • 16. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 17. [Multiple sclerosis: current therapies and future perspectives].
    Matsushita T.
    Nihon Rinsho; 2011 Nov 30; 69(11):2077-86. PubMed ID: 22111333
    [Abstract] [Full Text] [Related]

  • 18. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):387-401. PubMed ID: 20089952
    [Abstract] [Full Text] [Related]

  • 19. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 04; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 20. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
    Freedman MS.
    Eur J Neurol; 2014 Mar 04; 21(3):377-87, e18-20. PubMed ID: 24237582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 67.